BioSpace News Archive

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, announces the results of the Annual General Meeting of shareholders.

Escient Pharmaceuticals, a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-inflammatory disorders, announced positive results from a Phase 1 first-in-human study of EP262, a potent, highly selective small molecule antagonist of MRGPRX2.

Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced the receipt of U.S. Food and Drug Administration approval for the SurVeil™ drug-coated balloon.

Berkshire Biomedical Corporation announced today that two posters on the Company’s Computerized Oral Prescription Administration System (COPA) were presented yesterday at The College on Problems of Drug Development (CPDD) 85th Annual Scientific Meeting, currently being held through Wednesday, June 21, 2023 in Denver, CO.

Abcam plc, a global leader in the supply of life science research tools, filed an investor presentation with the U.S. Securities and Exchange Commission in connection with the Extraordinary General Meeting of the Company to be held on July 12, 2023 at 2:00pm || 9:00am.

OpGen, Inc. reported that its Principal Scientist Dr. Matthias Klein has presented results from the clinical trial for its Unyvero Urinary Tract Infection Panel during ASM Microbe’s In Depth Symposium session ‘The Year in Clinical Microbiology’ on June 17th in Houston, TX.

Zevra Therapeutics, Inc. announced its expected addition to the broad-market Russell 3000 ® Index and small-cap Russell 2000 ® Index in accordance with the 2023 Russell indexes annual reconstitution.

DiagnaMed Holdings Corp. is pleased to announce an update of CERVAI™, the Company’s proprietary AI brain health platform.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MAPLE-HCM a Phase 3 clinical trial comparing aficamten as monotherapy to metoprolol as monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment.

Oramed Pharmaceuticals Inc. announced today that it has been selected to present an oral abstract presentation at the American Diabetes Association’s 83rd Scientific Sessions, taking place between June 23-26, 2023 in San Diego, California.